Recancostat compositum® therapy does not prevent tumor progression in young cancer patients

被引：7

作者：

Bode, U ^{[1
]}

Hasan, C ^{[1
]}

Hülsmann, B ^{[1
]}

Fleischhack, G ^{[1
]}

机构：

[1] Univ Bonn, Dept Pediat Hematol Oncol, D-53113 Bonn, Germany

来源：

KLINISCHE PADIATRIE | 1999年 / 211卷 / 04期

关键词：

unconventional treatment; glutathione; reducing agents; cancer; solid tumors;

D O I：

10.1055/s-2008-1043813

中图分类号：

R72 [儿科学];

学科分类号：

100202 [儿科学];

摘要：

Stimulated by the public discussion about an antimalignant effect of the supplement drug Recancostat compositum(R) the drug was given in high doses to 16 young patients with intensively pretreated and measurable solid tumors for 1-30 weeks. In all patients the disease progressed, and they died 1-48 weeks following the start of the therapy. Side effects were not seen. This observation does not support the claim of an antitumor effect of Recancostat compositum(R).

引用

页码：353 / 355

页数：3

共 9 条

[1]

*ARZN DTSCH ARZT, 1996, DTSCH ARZTEBL, V93, P454

[2]

BUSCHEL G, 1997, MUNCH MED WSCHR, V139, P237

[3]

NEUROPROTECTIVE EFFECT OF REDUCED GLUTATHIONE ON CISPLATIN-BASED CHEMOTHERAPY IN ADVANCED GASTRIC-CANCER - A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL [J].

CASCINU, S ;

CORDELLA, L ;

DELFERRO, E ;

FRONZONI, M ;

CATALANO, G .

JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (01) :26-32

[4]

DALHOFF K, 1992, LIVER, V12, P341

[5]

DELAVEGA MCL, 1994, BIOCHEM J, V298, P99

[6]

Reduced glutathione and S-acetylglutathione as selective apoptosis-inducing agents in cancer therapy [J].

Donnerstag, B ;

Ohlenschlager, G ;

Cinatl, J ;

Amrani, M ;

Hofmann, D ;

Flindt, S ;

Treusch, G ;

Trager, L .

CANCER LETTERS, 1996, 110 (1-2) :63-70

[7]

REGRESSION OF AFLATOXIN-B1-INDUCED HEPATOCELLULAR CARCINOMAS BY REDUCED GLUTATHIONE [J].

NOVI, AM .

SCIENCE, 1981, 212 (4494) :541-542

[8]

GLUTATHIONE AND DETOXIFICATION [J].

TEDESCHI, M ;

BOHM, S ;

DIRE, F ;

ORIANA, S ;

SPATTI, GB ;

TOGNELLA, S ;

ZUNINO, F .

CANCER TREATMENT REVIEWS, 1990, 17 (2-3) :203-208

[9]

PREVENTION OF DOXORUBICIN-INDUCED CARDIOMYOPATHY BY REDUCED GLUTATHIONE [J].

VILLANI, F ;

GALIMBERTI, M ;

ZUNINO, F ;

MONTI, E ;

ROZZA, A ;

LANZA, E ;

FAVALLI, L ;

POGGI, P .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1991, 28 (05) :365-369

← 1 →